Skip to main content

Table 2 Characteristics of Patients

From: A nomogram based on biparametric magnetic resonance imaging for detection of clinically significant prostate cancer in biopsy-naïve patients

Variable

Training cohort

(n = 217)

Validation cohort

(n = 107)

csPCa

(n = 68)

Non-CsPCa

(n = 149)

P

CsPCa

(n = 36)

Non-CsPCa

(n = 71)

P

Age (Years, mean ± SD)

71.92 ± 8.99

67.34 ± 8.65

<0.01

69.80 ± 8.92

68.12 ± 7.56

0.15

tPSA (ng/mL, median [IQR])

19.50 (12.00-42.50)

10.00 (6.61-16.00)

<0.01

14.57 (8.50–61.00)

9.00 (6.00-15.75)

<0.01

fPSA (ng/mL, median [IQR])

2.29 (1.21–5.86)

1.44 (0.98–2.05)

<0.01

1.60 (0.99–7.76)

1.32 (0.77–2.49)

0.04

PV (ml, median [IQR])

37.14 (29.59-62.00)

55.00 (38.00-70.50)

<0.01

48.5 (35.40-56.55)

49.00 (34.04–77.75)

0.22

PSAD (ng/mL/mL, median [IQR])

0.49 (0.30–0.96)

0.18 (0.12–0.31)

<0.01

0.32 (0.20–1.18)

0.16 (0.12–0.26)

<0.01

Gleason score

  

≤ 3 + 3

149

71

3 + 4

37

12

4 + 3

18

4

4 + 4

2

4

> 4 + 4

11

16

  1. csPCa, clinically significant prostate cancer; fPSA, free prostate-specific antigen; IQR, interquartile range; tPSA, total prostate-specific antigen; PSAD, prostate-specific antigen density; PV, prostate volume; SD, standard deviation